Compare Stocks: EVOK, SPRO, TENX, and CING

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.76 +0.2%	$5.10	$3.16 ▼ $11.89	$69.22M	-0.88	88,931 shs	52,068 shs
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
SPRO Spero Therapeutics	$1.19 -5.6%	$1.20	$1.08 ▼ $3.08	$69.30M	1.5	820,293 shs	906,915 shs
TENX Tenax Therapeutics	$1.98 +2.6%	$4.37	$1.31 ▼ $19.40	$74.10M	0.92	3.44 million shs	2.03 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	-1.45%	-8.81%	-11.52%	+13.60%
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+136.05%
SPRO Spero Therapeutics	0.00%	-3.25%	-2.46%	-45.91%	-39.29%
TENX Tenax Therapeutics	0.00%	+9.39%	+11.24%	-87.19%	-74.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$4.76 +0.2%	$5.10	$3.16 ▼ $11.89	$69.22M	-0.88	88,931 shs	52,068 shs
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
SPRO Spero Therapeutics	$1.19 -5.6%	$1.20	$1.08 ▼ $3.08	$69.30M	1.5	820,293 shs	906,915 shs
TENX Tenax Therapeutics	$1.98 +2.6%	$4.37	$1.31 ▼ $19.40	$74.10M	0.92	3.44 million shs	2.03 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	0.00%	-1.45%	-8.81%	-11.52%	+13.60%
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+136.05%
SPRO Spero Therapeutics	0.00%	-3.25%	-2.46%	-45.91%	-39.29%
TENX Tenax Therapeutics	0.00%	+9.39%	+11.24%	-87.19%	-74.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.50	Moderate Buy	$27.00	467.23% Upside
EVOK Evoke Pharma	1.50	Reduce	N/A	N/A
SPRO Spero Therapeutics	2.25	Hold	$6.00	404.20% Upside
TENX Tenax Therapeutics	2.40	Hold	$14.00	607.07% Upside

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TENX, and CING Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	SPRO Spero Therapeutics	Compass Point Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral
9/14/2026	SPRO Spero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	SPRO Spero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
9/10/2026	TENX Tenax Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	TENX Tenax Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
8/31/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/28/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/23/2026	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$10.00 ➝ $9.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$0.31 per share	N/A
EVOK Evoke Pharma	$10.25M	1.85	N/A	N/A	$4.74 per share	2.32
SPRO Spero Therapeutics	$66.80M	1.04	$0.15 per share	7.82	$1.05 per share	1.13
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$10.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$22.45M	-$3.59	N/A	N/A	N/A	N/A	-238.40%	-128.67%	11/12/2026 (Estimated)
EVOK Evoke Pharma	-$5.35M	-$2.07	N/A	N/A	N/A	-36.23%	-101.40%	-31.86%	N/A
SPRO Spero Therapeutics	$8.57M	$0.11	10.82	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-61.54%	-57.42%	11/11/2026 (Estimated)

Latest EVOK, SPRO, TENX, and CING Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CING Cingulate	-$0.63	-$0.45	+$0.18	-$0.45	$0.17 million	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	3.50	3.50
EVOK Evoke Pharma	N/A	1.27	1.22
SPRO Spero Therapeutics	N/A	6.12	6.12
TENX Tenax Therapeutics	N/A	15.07	15.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
EVOK Evoke Pharma	N/A
SPRO Spero Therapeutics	25.60%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.30%
EVOK Evoke Pharma	2.29%
SPRO Spero Therapeutics	2.90%
TENX Tenax Therapeutics	10.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	14	14.54 million	13.77 million	Not Optionable
EVOK Evoke Pharma	4	1.72 million	1.68 million	Not Optionable
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable
TENX Tenax Therapeutics	16	37.42 million	33.38 million	Not Optionable

EVOK, SPRO, TENX, and CING Headlines

Recent News About These Companies

Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

September 30, 2026 | marketbeat.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Now Rated "Hold" by Wall Street Brokerages

September 29, 2026 | americanbankingnews.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Now Rated "Hold" by Wall Street Analysts

September 29, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Director Declan Doogan Purchases 53,000 Shares of Stock

September 18, 2026 | insidertrades.com

Declan Doogan Purchases 53,000 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 17, 2026 | marketbeat.com

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

September 16, 2026 | theglobeandmail.com

Tenax Therapeutics (NASDAQ:TENX) CEO Acquires $11,280.00 in Stock

September 16, 2026 | insidertrades.com

Tenax Therapeutics (NASDAQ:TENX) CEO Christopher Thomas Giordano Buys 6,000 Shares

September 15, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Buys $1,602,000.00 in Stock

September 9, 2026 | insidertrades.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Purchases 900,000 Shares of Stock

September 8, 2026 | marketbeat.com

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

September 4, 2026 | insidermonkey.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Hold" by Brokerages

September 4, 2026 | marketbeat.com

Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases $322,304.40 in Stock

September 3, 2026 | insidertrades.com

Guggenheim downgrades Tenax Therapeutics (TENX)

September 2, 2026 | msn.com

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

Tenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures

August 30, 2026 | rttnews.com

Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

August 30, 2026 | seekingalpha.com

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

August 29, 2026 | quiverquant.comQ

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

August 29, 2026 | globenewswire.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Acquires 107,374 Shares

August 25, 2026 | insidertrades.com

Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

August 19, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, SPRO, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

$4.76 +0.01 (+0.21%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.86 +0.10 (+2.10%)

As of 10/2/2026 07:34 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Evoke Pharma NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Spero Therapeutics NASDAQ:SPRO

$1.19 -0.07 (-5.56%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.21 +0.02 (+1.76%)

As of 10/2/2026 07:56 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Tenax Therapeutics NASDAQ:TENX

$1.98 +0.05 (+2.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.97 -0.01 (-0.51%)

As of 10/2/2026 07:55 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TENX, and CING Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, SPRO, TENX, and CING Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, SPRO, TENX, and CING Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, SPRO, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

Evoke Pharma NASDAQ:EVOK

Spero Therapeutics NASDAQ:SPRO

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TENX, and CING Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, SPRO, TENX, and CING Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, SPRO, TENX, and CING Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, SPRO, TENX, and CING Company Descriptions

Cingulate NASDAQ:CING

Evoke Pharma NASDAQ:EVOK

Spero Therapeutics NASDAQ:SPRO

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools